Although imatinib is firmly established as an effective therapy for newly diagnosed patients
with chronic myeloid leukemia (CML), the field continues to advance on several fronts. In this …

State-of-the-art in the treatment of chronic myeloid leukaem... : Current Opinion in Oncology
State-of-the-art in the treatment of chronic myeloid leukaemia : Current Opinion in Oncology …

The introduction of tyrosine kinase inhibitors (TKIs) has changed the landscape of therapy
for chronic myelogenous leukemia (CML). Once considered an incurable malignancy, CML …

The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed
dramatically in the past 15 years. This has been due to the development of tyrosine kinase …

Introduction: As survival of patients with chronic myeloid leukemia (CML) is dramatically
improved over time, the prevalence of the disease is steadily increasing. At this moment, five …

The introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), has
revolutionized the treatment of chronic myeloid leukemia (CML). By directly targeting the Bcr …

Opinion statement Discovery of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI) in
the therapy of patients with chronic myeloid leukemia (CML) is perhaps the most popular …

The advent of tyrosine kinase inhibitor (TKI) therapy has considerably improved the survival
of patients suffering chronic myelogenous leukemia (CML). Indeed, inhibition of BCR-ABL …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

During two centuries, advances in medicine and medical research have helped to
understand the pathophysiology of chronic myelogenous leukemia (CML). This hematologic …